F
olates are important cofactors in the transfer and utilization of 1-carbon moieties and play a key role in the synthesis of nucleic acids and methionine regeneration. It has long been known that florid folate deficiency causes a defect in DNA synthesis, leading to megaloblastic macrocytic anemia. Now, Ͼ55 years after the discovery and synthesis of folate, 1 it is recognized that more discrete deficiency of this essential nutrient is also associated with an increased risk of morbidity unrelated to anemia.
There is irrefutable evidence that folate deficiency or abnormalities in folate metabolism during pregnancy are associated with an increased risk of developmental abnormalities, particularly neural tube defects, 2 whereas folate supplementation can significantly reduce the occurrence and recurrence of such disorders. 3 Other potential manifestations of folic acid deficiency include neurological and neuropsychiatric disorders 4, 5 and the development of certain neoplasms and preneoplastic conditions. 6 Furthermore, folic acid deficiency has been associated with a predisposition to atherosclerotic cardiovascular disease.
In the present article, we will review recent developments regarding the role of folates in cardiovascular disease. In addition, we will discuss potential underlying mechanisms and possible clinical and/or dietary consequences.
Folate, Vascular Function, and Cardiovascular Disease Risk
In the past 3 years, several intervention studies have shown the benefits of folate therapy on endothelial function (Table) . Endothelial dysfunction, assessed as impaired vasodilator response to mechanical or pharmacological stimuli, has been increasingly recognized as a surrogate end point for cardiovascular risk. A close correlation has been observed between the presence of cardiovascular risk factors and endothelial vasodilator dysfunction. 7 Several investigators have found an association between endothelial dysfunction and myocardial ischemia. 8, 9 Importantly, 2 recent reports have demonstrated in long-term follow-up that endothelial dysfunction is associated with a higher incidence of cardiovascular events and increased progression of atherosclerotic disease. 10, 11 Together, available data strongly suggest that improvement of endothelial function may be associated with reduced cardiovascular risk. Two recent studies have demonstrated that folic acid supplementation in patients with asymptomatic hyperhomocysteinemia can improve endothelial function, measured as enhanced flow-mediated vasodilatation. 12, 13 In addition, endothelial function was improved after folate therapy in hyperhomocysteinemic patients with established coronary artery disease, 14 -16 whereas folic acid supplementation also caused a reduction in the rate of progression of the ultrasound-determined extracranial carotid artery plaque area in patients with premature atherosclerosis and hyperhomocysteinemia. 17 More recently, high single-dose and multipledose folic acid administration has been shown to prevent the temporary endothelial dysfunction induced by postmethionine-load hyperhomocysteinemia in healthy volunteers. 18, 19 These data support the hypothesis that the lowering of homocysteine in hyperhomocysteinemic patients may reduce cardiovascular risk.
Interestingly, several investigators have also reported beneficial effects of folates in nonhyperhomocysteinemic patients. A recent study has shown that folic acid can prevent endothelial dysfunction induced by continuous nitroglycerin treatment in healthy volunteers. 20 We have recently demonstrated that intra-arterial administration of 5,10-methylenetetrahydrofolate and oral supplementation of folic acid can restore endothelial function in patients with familial hypercholesterolemia but with normal plasma homocysteine levels 21, 22 (Figure 1 ). In addition, preliminary data from our group suggest a beneficial effect of folate on endothelial dysfunction in diabetes (R. Van Etten, unpublished data, 2001). Vermeulen et al 23 have demonstrated that folic acid therapy decreases the occurrence of abnormal exercise ECG tests in healthy siblings of patients with premature atherothrombotic disease. Furthermore, we have demonstrated that folic acid treatment can prevent endothelial dysfunction due to oral fat loadinduced hyperlipidemia in healthy volunteers. 24 Importantly, we 21 and others 16, 18 have shown a beneficial effect of folates on endothelial function independent of changes in plasma homocysteine levels.
The above observations suggest a role for folate supplementation in cardiovascular disease. Naturally, for definite conclusions, confirmation by large, controlled, prospective trials with hard clinical end points will be essential. Unfortunately, the results of such trials, which are currently ongoing, will have to be awaited. 25 Various epidemiological studies seem to support a link between folate status and atherosclerotic vascular disease. In the European Concerted Action Project, a large multicenter case-control study including 750 cases and 800 controls, it was demonstrated that low serum folate levels are related to increased cardiovascular disease risk. 27 Similar findings have been reported in smaller cross-sectional studies, 28 -31 whereas others could not confirm such an association. [32] [33] [34] In subsets of several prospective studies, such as the National Health and Nutrition Examination Survey, [35] [36] [37] the Kuopio Ischemic Heart Disease Risk Factor Study, 38 the Framingham Heart Study, 39 and the Nutrition Canada Survey, 40 an inverse relation between folate status and atherosclerotic vascular disease has also been demonstrated, although this could not be confirmed by others (the Physicians' Health Study 41 and Atherosclerosis Risk in Communities Study 42 ). Interestingly, in the Nurses' Health Study and in the Kuopio Ischemic Heart Disease Risk Factor Study, it was demonstrated that 20% of the individuals with the highest consumption of folate had significantly less cardiovascular disease than did those with the lowest consumption. 43, 44 On the other hand, antifolate therapy with methotrexate, an antirheumatic drug that impairs folate metabolism, has recently been suggested to promote atherosclerosis. 45 Additionally, a common mutation of 5,10-methylenetetrahydrofolate reductase (MTHFR), which causes increased thermolability and reduced activity of the enzyme catalyzing the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF, the main form of folate in the circulation 46 ), has also been reported by some to be a risk factor for vascular disease. [47] [48] [49] [50] [51] Several other large studies could not confirm such an association. [52] [53] [54] [55] [56] Population differences and differences in folate status have been suggested to be responsible for these different study results. 57, 58 
Potential Mechanisms Underlying a Beneficial Effect of Folates in Cardiovascular Disease

Lowering of Homocysteine Levels
Many randomized controlled trials have demonstrated that treatment with natural dietary folate or the synthetic folic acid (pteroylmonoglutamic acid) significantly reduces plasma homocysteine levels, even when plasma levels of homocysteine and folate are already in the normal range. 59, 60 This homocysteine-lowering effect of folate can be explained by its actions as a substrate in the remethylation of homocysteine to methionine. Elevated homocysteine levels have been suggested to be a causal factor in cardiovascular disease. Thus, a beneficial effect of folates on cardiovascular risk might be explained by their effect on homocysteine plasma levels. Indeed, many cross-sectional and retrospective casecontrol studies have demonstrated a positive association between plasma homocysteine levels and cardiovascular risk. However, results from large prospective cohort studies are less convincing; a recent review of 7 prospective studies found no association or only a small association between plasma homocysteine levels and cardiovascular disease [61] [62] [63] [64] (for comprehensive review on homocysteine and cardiovascular disease, see Hankey and Eikelboom 26 ). Several pathogenetic mechanisms, based on in vitro experiments, have been proposed. 64 However, the clinical relevance of these in vitro experiments has been questioned, mainly because of the much higher homocysteine concentrations used in vitro than are used in patients. Definite proof that homocysteine is a causal factor for cardiovascular disease is still lacking. Alternatively, folate deficiency may be the primary cause of the increased risk of vascular disease, with elevated homocysteine levels a marker for low folate status rather than a pathogenetic factor. Distinguishing between high homocysteine and low folate as a primary etiological factor in cardiovascular disease may not be feasible from clinical studies, considering their close metabolic relationship. For example, acute post-methionineload hyperhomocysteinemia in healthy volunteers has been shown to induce endothelial dysfunction. 65 Although this has been viewed to be supportive of the causal relation between elevated homocysteine levels and cardiovascular disease, it may also be explained by the decrease in 5-MTHF levels that has been shown to occur after methionine loading. 66 Thus, whether the homocysteine-lowering effect of folates contributes to their beneficial effects on cardiovascular risk has not been established. However, our recent observations that the beneficial effects of folate in hypercholesterolemia occurred independent of a homocysteine-lowering effect 21 indicate that other mechanisms must also be involved.
Antioxidant Actions
Ample evidence implicates oxidative stress in the pathogenesis of cardiovascular disease. 67 Oxidative stress is defined as a disturbance in the equilibrium between the production of reactive oxygen species (free radicals, eg, superoxide) and Figure 1 . Percent change in forearm blood flow after stimulation of endothelium-independent and endothelium-dependent vasodilation with sodium nitroprusside (SNP) and serotonin (5-HT) and after NO synthase inhibition with N G -monomethyl-L-arginine (L-NMMA) in young patients with familial hypercholesterolemia (FH) without macrovascular disease at baseline, after placebo, and after folic acid treatment (5 mg/d for 4 weeks) and in control subjects. There was no effect of folic acid supplementation in control subjects or on endothelium-independent vasodilation. Folic acid supplementation significantly enhanced endotheliumdependent vasodilation in FH patients. There was a trend toward improvement in basal NO activity. 22 FAV indicates forearm value.
antioxidant defenses. Endothelial dysfunction, a crucial early event in atherogenesis, is characterized by reduced bioavailability of endothelium-derived NO, which has been found to be due, at least in part, to enhanced oxidant degradation of NO in most cardiovascular risk factors. 68 Several antioxidants have been shown to reverse endothelial dysfunction in patients with coronary artery disease or increased risk of premature atherosclerosis. 65,69 -75 In a series of in vitro experiments, we have demonstrated that folates possess antioxidant potential. Using lucigeninenhanced chemiluminescence, we observed that 5-MTHF could reduce superoxide generation by 2 superoxidegenerating systems: xanthine oxidase/hypoxanthine and endothelial NO synthase (eNOS). 21 Others have shown that folate abolished the homocysteine-induced increases in endothelial superoxide. 16 Recently, we could confirm the superoxide-scavenging capacity of 5-MTHF by electron paramagnetic resonance, with the use of 5-(Diethoxyphosphoryl)-5-methyl-L-pyrroline N-oxide as a spin trap for superoxide. 76 However, using this method, we also observed that the scavenging potency of 5-MTHF is Ϸ20-fold lower than the scavenging effects of vitamin C, a well-known antioxidant vitamin. Thus, although compared with physiological vitamin C concentrations, folate clearly does exert antioxidant actions, given its lower potency and much lower plasma levels obtained in vivo, the relevance of such a direct antioxidant effect of folate in vivo is uncertain.
Interestingly, several animal and human studies do support a benefit of folates on the redox state. In rats, folate deficiency has been shown to increase lipid peroxidation and decrease cellular antioxidant defense. 77, 78 Furthermore, we observed in healthy volunteers that the beneficial effect of folates on postprandial endothelial dysfunction corresponded with a decreased urinary excretion of malondialdehyde, the radical-damage end product. 24 We hypothesize that an effect of folate on the NO-synthesizing enzyme eNOS may provide an explanation for the observed effects on oxidative stress and cardiovascular risk. Figure 2 shows the interactions of folate with eNOS. In physiological situations, eNOS catalyzes the formation of NO by incorporating molecular oxygen into the substrate L-arginine, a reaction that requires NADPH, the allosteric activator calmodulin, and several cofactors, such as tetrahydrobiopterin (BH4). 79 Recent data illustrate that under certain pathophysiological conditions, eNOS can "switch" from mainly NO synthesis to production of superoxide, 80 -82 a process called eNOS uncoupling (ie, uncoupling of NADPH oxidation and NO synthesis). Addition of the essential cofactor BH4 has previously been shown to reduce superoxide production by eNOS in vitro 81, 83 and to improve NO availability in vivo, 84, 85 suggesting restoration of eNOS uncoupling by BH4. In a recent series of in vitro experiments, we found that 5-MTHF can also influence the enzymatic activity of uncoupled eNOS: 5-MTHF reduces superoxide generation (more than can be explained by just a scavenging effect) and increases NO synthesis. 76 Interestingly, these effects were observed only in partially BH4-replete, but not in BH4-free, eNOS.
Interactions With eNOS
Several mechanisms may underlie the observed folateinduced BH4-dependent potentiation of eNOS. Recently, the presence of a pteridine-binding domain in NO synthase with similarities to the folate binding site of dihydrofolate reductase has been reported. 86 This site may act as a locus through which 5-MTHF can facilitate the electron transfer by BH4 from the reductase domain of eNOS to heme. 87 Alternatively, 5-MTHF may enhance the binding of BH4 to eNOS. 5-MTHF may also act by increasing BH4 availability. This may occur through a chemical stabilization of BH4, as has recently been described for ascorbic acid. 88 Furthermore, it has been suggested that folates may stimulate regeneration of BH4 from the inactive oxidized quinoid dihydrobiopterin. 89 Indeed, high-dose folate supplementation has been shown to produce clinical improvement in children with BH4 deficiency. 90 The ameliorative influence of folates on eNOS suggests a more pronounced benefit in the early phases of atherogenesis and less of a benefit on the more advanced stages, given the reduced eNOS expression observed in more advanced atherosclerosis. 91 Indeed, only modest improvement of endothelial function has been observed after folate supplementation in established coronary atherosclerosis, 14 whereas in dialysis patients or in patients with predialysis renal failure, no effect of folate treatment on endothelial dysfunction could be found. [92] [93] [94] Do We Need to Increase Our Folate Intake?
Over the years, insights on desirable folate intake have dramatically changed. Not long ago, folate sufficiency was defined as just an absence of megaloblastic anemia. In 1989, the Food and Nutrition Board in the United States even lowered the recommended dietary allowance of folate because of the low incidence of anemia due to folate deficiency. Under certain circumstances, eNOS uncoupling can occur: a switch from the coupled (mainly NO-synthesizing) state to the uncoupled (superoxide-producing) state. The beneficial effects of folates may be explained by different mechanisms: I, BH4 rescue or BH4 stabilization, in which folates may stimulate endogenous BH4 regeneration from quinoid dihydrobiopterin (q-BH 2 ) or lead to chemical stabilization of BH4; II, antioxidant effects, in which folates may act as direct antioxidants; and III, direct effect on eNOS, in which folates have been shown to reduce superoxide generation and increase NO synthesis in a BH4-dependent manner, suggesting a direct effect on eNOS. THF indicates tetrahydrofolate; 7,8-BH 2 , 7,8-dihydrobiopterin.
Verhaar et al Folates and Cardiovascular Disease
However, during the past decade, marginal folate deficiency has been increasingly viewed as an important public health issue. Primarily, this is due to the consistent observation that folate deficiency in pregnancy is associated with birth defects. The studies reviewed above raise the question of whether the relatively low folate levels in the present-day western-style diet may also contribute to the excess cardiovascular morbidity and mortality in industrialized countries. It is well known that dietary factors can influence the development of atherosclerosis. Recently, several dietary factors, such as an oral fat load, 24 a single high-fat meal, 95 an oral methionine load, or dietary animal protein, 96 have been shown to cause temporary endothelial dysfunction in healthy volunteers. Importantly, folic acid supplementation could completely prevent the observed diet-induced impairment in endothelial function. 18, 19, 24 These data provide support for a protective role of folates against vascular insults. Moreover, they suggest that present-day folate intake may be too low to protect against the proatherogenic effects of our present diets, which are relatively high in fat and animal protein (methionine). Consistently, monkeys, which do not normally develop atherosclerotic disease, developed marked vascular dysfunction when fed a folate-depleted methionine-rich diet. 97 Interestingly, several human studies have shown an inverse association between fruit and vegetable (high-folate) consumption and risk of cardiovascular disease. 98 -101 Of course, fruit and vegetables may contain other vascular-protective substances, which may explain the favorable effects. In a recent large prospective study, a higher reported intake of folate was associated with reduced incidence of nonfatal myocardial infarction and fatal coronary heart disease. 43 Thus, increased folate intake may be desirable not only in certain subgroups but also in the general population in western countries. Improved folate status can be accomplished by increasing natural dietary folate (a diet rich in vegetables and citrus fruit) supplementation with the synthetic folic acid (pteroylmonoglutamic acid), which is heat stable and approximately twice as bioavailable, or folic acid food fortification. For all 3 methods, the potential to increase serum folate has been demonstrated. 59, 60, 102 However, the actual effectiveness of the first 2 methods may be low because of poor compliance: surveys to evaluate folic acid supplementation for the prevention of birth defects uncovered that only a small minority of pregnant women had, in fact, taken advised folic acid supplements. 103 This has caused the Food and Drug Administration to introduce folic acid fortification of "enriched" cereal grains (1.4 mg/kg grain) in the Unites States in 1998. Similar fortification programs were introduced in Canada and several other industrialized countries. The Framingham Offspring Study has demonstrated that this policy has led to a substantial improvement in folate status in a population of middle-aged and older adults (mean folate concentrations increased from 11 to 23 nmol/L). 104 It will be very interesting to discover whether this level of fortification will influence cardiovascular morbidity and mortality.
Present data suggest that criteria for "folate sufficiency" may have to be redefined. Preferentially, recommendations on folate intake should be tailored to the needs of the individual patient or specific subgroups. Most studies on the effects of folates on cardiovascular end points have, thus far, shown the benefits of relatively large quantities of folic acid (Ն5 mg every day). No dose-response studies have been reported. It is highly likely that folate requirements will vary between groups. Increased folate demands have been suggested to occur during pregnancy. 105 Additionally, nutritional but also genetic factors, such as MTHFR polymorphisms, 58 may influence folate requirements. Furthermore, certain conditions may be associated with increased folate needs. For example, in vitro experiments have shown that superoxide may induce folate cleavage. 106 Such increased folate catabolism may lead to enhanced folate needs in patients who are exposed to increased oxidative stress, such as hypercholesterolemic and diabetic patients. Increased oxidative stress may also lead to increased consumption of folate because of its role as an antioxidant or in BH4 regeneration. Considering the amount of known and probably also unknown factors influencing folate metabolism, the assessment of folate sufficiency may be complicated. Possibly, homocysteine plasma levels may provide important information with low homocysteine levels (as low as possible), reflecting adequate folate status. Alternatively, unimpaired postprandial endothelial function may indicate folate sufficiency.
Safety Considerations
In general, folic acid supplementation is considered safe. 107 Some adverse effects were described in case reports and uncontrolled studies, but these could not be substantiated by further studies. However, there is some concern about folic acid therapy in people with subclinical cobalamin (vitamin B 12 ) deficiency, a relatively common disorder in the elderly 108 and in strict vegetarians. 109 Folic acid therapy in these patients may mask the hematologic manifestations of the disorder and allow progression of the neurological damage, including spinal cord injury. This induced several investigators to suggest the inclusion of cobalamin in folic acid supplements. Additionally, increased awareness of cobalamin deficiency in the population must be pursued. In our opinion, if the benefits of folic acid supplementation on hard cardiovascular end points can be confirmed in large clinical trials, the profits will, by far, outweigh the potential adverse effects. Of course, we should stay on the alert to identify potential adverse effects at an early stage.
Conclusions
Overall, available data strongly suggest a benefit of folate supplementation in lowering cardiovascular risk. Observational studies demonstrated an association between folate levels and cardiovascular morbidity and mortality, and a plausible biological mechanism that was based on in vitro experiments was presented. Additionally, an increasing number of interventional studies have confirmed the benefit of folates on surrogate end points. Of course, data from large, randomized, prospective trials are required to substantiate these findings. Such trials investigating the effects of folates on hard clinical cardiovascular end points are currently ongoing. 25, 26 
